Page 24 - Company Codes News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Reimbursement proceedings with publicly funded health plans ready to commence MONTREAL, June 1, 2021 /PRNewswire/ - Valeo or the Company ), a Canadian pharmaceutical company, announced today that private payer health plans currently covering 80% of privately insured lives in Canada have agreed to provide reimbursement for Enerzair Breezhaler and Atectura Breezhaler. Enerzair Breezhaler and Atectura Breezhaler are two new innovative asthma therapies which have been approved for use in Canada. Asthma therapies are largely covered by private payers representing 50% of the total market. Reimbursement of both Enerzair and Atectura are now available for the majority of privately covered lives in Canada and reimbursement proceedings with public health plans are ready to commence , said Frederic Fasano, Valeo s President and Chief Operating Officer. Both drugs have demonstrated, in head-to-head compararison versus standard of care, significant clinical improvement of asthma relate

Enerzair breezhalerValeo pharmaAtectura breezhalerFrederic fasanoCompany codesValeo pharma incChief operatingNeurodegenerative diseasesAleo pharma provides update on private payer reimbursement for enerzair breezhaler and atecturaவளேோ பார்மாஃப்ரெடரிக் பசாணோநிறுவனம் குறியீடுகள்வளேோ பார்மா இன்க்தலைமை இயங்குகிறது